title: Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?
abstract: Incretin mimetics offer a new modality in diabetes treatment. This modality is based on the effects of the naturally occurring glucoregulatory gut hormone glucagon-like peptide-1 (GLP-1), which counteracts several pathophysiologic traits in type 2 diabetes. GLP-1 receptor agonists with extended half-lives entailing fewer injections and presumably an improved throughout-the-day glycemic control are in clinical development. This article summarizes the physiologic effects of GLP-1; the effects of the already marketed GLP-1 analogues for daily dosing, exenatide and liraglutide; and reviews the presently published data (with emphasis on clinical pharmacokinetics, efficacy, and safety) on GLP-1 agonists, which currently are in development and intended for once-weekly dosing: albiglutide/albugon, CJC-1131, CJC-1134-PC, exenatide once weekly, and taspoglutide.
authors.affiliation: Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
authors.forename: Mikkel
authors.initials: M
authors.lastname: Christensen
authors.forename: Filip K
authors.initials: FK
authors.lastname: Knop
mesh_terms: D000818:Animals; D004334:Drug Administration Schedule; D004353:Drug Evaluation, Preclinical; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage / Q000819:agonists* / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000494:pharmacology*; D000069450:Liraglutide; D010455:Peptides / Q000008:administration & dosage / Q000494:pharmacology*; D004364:Pharmaceutical Preparations; D014688:Venoms / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D007004:Hypoglycemic Agents; D010455:Peptides; D004364:Pharmaceutical Preparations; D014688:Venoms; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide